Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Structure TherapeuticsGPCR +0.70%32 14-Day RSI is 54.12 as of Jul. 23, 2026. GuruFocus rates GPCR with a GF Score™ of 32/100. Among 1,424 Biotechnology companies, Structure Therapeutics ranks worse than 78.58% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Structure Therapeutics 14-Day RSI Related Terms
GPCR vs PBLS, IDYA, ELVN: 14-Day RSI Comparison
For the Biotechnology subindustry, Structure Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Structure Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Structure Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Structure Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Structure Therapeutics (GPCR) has a 14-Day RSI of 54.12 as of Jul. 23, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Structure Therapeutics and its competitors. According to the industry distribution chart, Structure Therapeutics ranks #1119 out of 1424 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Structure Therapeutics' 14-Day RSI too high?
Structure Therapeutics' current 14-Day RSI is 54.12. The Biotechnology industry median 14-Day RSI is 45.23. Structure Therapeutics' value of 54.12 is 19.7% above this industry median. Based on the distribution chart, Structure Therapeutics ranks #1119 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' 14-Day RSI compare to PBLS and IDYA?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #1119 out of 1424 companies for 14-Day RSI. This places Structure Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 45.23. Structure Therapeutics' value of 54.12 is 19.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.23, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Structure Therapeutics's current 14-Day RSI of 54.12 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Structure Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Structure Therapeutics's current 14-Day RSI is 54.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current 14-Day RSI of 54.12. The current 14-Day RSI is 54.12 and 19.7% above the Biotechnology industry median of 45.23. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current 14-Day RSI is 54.12 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score
Get the complete analysis for GPCR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GPCR has been successfully added to your 
